AKESO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.05 HKD | -22.89% |
|
-23.92% | -20.15% |
| May. 24 | Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut | MT |
| May. 24 | Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20% | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 25,172 | 22,635 | 31,941 | 35,470 | 29,738 | - | - |
| Enterprise Value (EV) 1 | 22,680 | 20,843 | 31,716 | 35,470 | 31,450 | 30,158 | 29,515 |
| P/E ratio | -19.4 x | -21 x | -26.7 x | 17.4 x | -65.5 x | 109 x | 22.8 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 100 x | 38.1 x | 7.84 x | 11.2 x | 6.95 x | 4.91 x |
| EV / Revenue | - | 92.4 x | 37.9 x | 7.84 x | 11.9 x | 7.05 x | 4.87 x |
| EV / EBITDA | -17.6 x | -16 x | -25.9 x | - | -110 x | 48.1 x | 17.8 x |
| EV / FCF | -19.3 x | -12.1 x | -15.5 x | - | -52.8 x | 248 x | 22.3 x |
| FCF Yield | -5.17% | -8.24% | -6.44% | - | -1.89% | 0.4% | 4.48% |
| Price to Book | 6.31 x | 7.16 x | 11.9 x | 7.53 x | 6.47 x | 5.81 x | 4.56 x |
| Nbr of stocks (in thousands) | 787,057 | 817,057 | 841,057 | 841,057 | 865,857 | - | - |
| Reference price 2 | 31.98 | 27.70 | 37.98 | 42.17 | 34.34 | 34.34 | 34.34 |
| Announcement Date | 3/31/21 | 3/30/22 | 3/15/23 | 3/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 225.6 | 837.7 | 4,526 | 2,653 | 4,277 | 6,062 |
| EBITDA 1 | -1,290 | -1,302 | -1,225 | - | -285.2 | 626.5 | 1,655 |
| EBIT 1 | -1,313 | -1,351 | -1,331 | 2,049 | -445.5 | 379.6 | 1,371 |
| Operating Margin | - | -598.89% | -158.92% | 45.26% | -16.79% | 8.88% | 22.62% |
| Earnings before Tax (EBT) 1 | -1,321 | -1,258 | -1,422 | 1,943 | -486.2 | 291 | 1,532 |
| Net income 1 | -1,177 | -1,075 | -1,168 | 2,028 | -430.6 | 259.2 | 1,278 |
| Net margin | - | -476.42% | -139.48% | 44.81% | -16.23% | 6.06% | 21.08% |
| EPS 2 | -1.650 | -1.320 | -1.420 | 2.420 | -0.5240 | 0.3148 | 1.507 |
| Free Cash Flow 1 | -1,173 | -1,717 | -2,043 | - | -595.6 | 121.6 | 1,323 |
| FCF margin | - | -761.15% | -243.88% | - | -22.45% | 2.84% | 21.82% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 19.41% | 79.94% |
| FCF Conversion (Net income) | - | - | - | - | - | 46.9% | 103.54% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/31/21 | 3/30/22 | 3/15/23 | 3/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 97.03 | - | 674.5 | 3,677 | 849.4 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | 2,482 | -433.9 |
| Operating Margin | - | - | - | - | 67.51% | -51.09% |
| Earnings before Tax (EBT) 1 | - | -812 | - | -730.3 | 2,490 | -547 |
| Net income 1 | -424.9 | - | -630.4 | -538 | 2,525 | -496.7 |
| Net margin | - | - | - | -79.75% | 68.67% | -58.48% |
| EPS | -0.5200 | - | -0.7700 | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/23/21 | 3/30/22 | 8/23/22 | 3/15/23 | 8/29/23 | 3/18/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1,712 | 420 | - |
| Net Cash position 1 | 2,492 | 1,792 | 225 | - | - | - | 223 |
| Leverage (Debt/EBITDA) | - | - | - | - | -6.003 x | 0.6712 x | - |
| Free Cash Flow 1 | -1,173 | -1,717 | -2,043 | - | -596 | 122 | 1,323 |
| ROE (net income / shareholders' equity) | -74% | -33.9% | -40.3% | 55.4% | -8.83% | 5.81% | 21% |
| ROA (Net income/ Total Assets) | -42.6% | -24.8% | -22.7% | 27.6% | -3.44% | 5.25% | 13.8% |
| Assets 1 | 2,765 | 4,331 | 5,151 | 7,339 | 12,504 | 4,938 | 9,281 |
| Book Value Per Share 2 | 5.060 | 3.870 | 3.200 | 5.600 | 5.310 | 5.910 | 7.530 |
| Cash Flow per Share 2 | -0.9800 | -1.230 | -1.500 | 2.950 | -0.1000 | 0.4100 | 1.520 |
| Capex 1 | 556 | 716 | 802 | - | 336 | 297 | 261 |
| Capex / Sales | - | 317.39% | 95.8% | - | 12.67% | 6.95% | 4.3% |
| Announcement Date | 3/31/21 | 3/30/22 | 3/15/23 | 3/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
34.34
CNY
Average target price
54.92
CNY
Spread / Average Target
+59.90%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.15% | 4.11B | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- 9926 Stock
- Financials Akeso, Inc.
